A LinkedIn post from Circulate highlights a podcast discussion on Therapeutic Plasma Exchange, or TPE, featuring CEO Dr. Brad Younggren. The post points to TPE’s potential role in preventive and longevity medicine, focusing on removing toxins, inflammatory markers, and microplastics from the bloodstream.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, the conversation covers existing human trial data, biomarker-driven treatment frequency, and upcoming research on circulatory-based interventions. For investors, this emphasis on scientific validation and biomarker-guided care may signal Circulate’s intent to position itself at the intersection of longevity, personalized medicine, and device- or procedure-based therapeutics.
If future clinical data support efficacy and safety, the approach suggested in the post could open pathways to premium preventive-care offerings and partnerships with longevity clinics or healthcare providers. However, any commercial impact is likely contingent on regulatory considerations, reimbursement frameworks, and broader medical-community adoption of TPE for non-traditional, preventive indications.
The focus on microplastics and circulating toxins also aligns with rising public and scientific interest in environmental health factors, which may help Circulate differentiate its platform. Investors may view the highlighted research agenda as an indicator of longer-term optionality rather than near-term revenue, with execution risk tied to clinical outcomes and market education requirements.